Reducing COPD Rehospitilizations One Patient at a Time

Quality Improvement
Curriculum:
Global Initiatives for Chronic Obstructive Lung Disease (GOLD) strategies to diagnose and treat COPD.
Credits:
0.50 AMA PRA Category 1 Credit(s)™
Launch Date:
August 01, 2019
Expiration Date:
August 01, 2020

Primary Audience:

Primary Care physicians

Relevant Terms:

COPD, Quality Improvement

Emily S. Wan, MD

Assistant Professor of Medicine
Channing Division of Network Medicine
Brigham & Women's Hospital
Harvard Medical School
Boston, MA

After graduating with a degree in Molecular Biophysics and Biochemistry from Yale University, Dr. Wan graduated summa cum laude from the State University of New York Downstate Medical Center and completed a residency and fellowship at Massachusetts General Hospital and the Harvard Combined Pulmonary & Critical Care program. 

She is currently on faculty at Harvard Medical School, Brigham and Women's Hospital, and the Veterans Affairs Boston Healthcare System where she attends in the medical intensive care unit, the inpatient and outpatient pulmonary services, and pulmonary rehabilitation program.  

Dr. Wan has been involved in research on the epidemiology, genetics, and genomics of COPD and chronic lung diseases, including the landmark COPDGene Study and has received research grants from the Parker B. Francis Foundation, Alpha-1 Foundation, and the Veterans Affairs Rehabilitation Research and Development service.  In addition to clinical service and research, Dr. Wan has served as an invited speaker at the Harvard T.H. Chan School of Public Health, the American Thoracic Society, and Pri-Med education courses.

Amit Singh Tibb, MD FCCP

Amit Singh Tibb, MD FCCP
Chief Quality Officer, Valley Medical Group 
Clinical Assistant Professor of Medicine 
Albert Einstein College of Medicine
Bronx, NY

As Chief Quality Officer at Valley Medical Group, Dr. Tibb is responsible for directing clinical quality and performance improvement initiatives.  In addition to his role at Valley Medical Group, Dr. Tibb serves as The Valley Hospital's Director of Palliative Medicine. 

Dr. Tibb came to Valley from Albert Einstein College of Medicine/Jacobi Medical Center in Bronx, N.Y., where he served as Director of the Medical Intensive Care Unit and an Assistant Professor and Attending Physician in the hospital's pulmonary critical care and hospice/palliative care medicine departments. Dr. Tibb retains his title of Assistant Professor of Medicine at Albert Einstein College of Medicine.

After completing his residency in internal medicine at Albert Einstein College of Medicine/Jacobi Medical Center, Dr. Tibb went on to complete fellowship training in multiple subspecialties at Montefiore Medical Center in Bronx, N.Y. He is now American board certified in pulmonary medicine, critical care, neurocritical care, palliative care/hospice medicine and internal medicine. Dr. Tibb is also fellowship trained in clinical quality and patient safety, as well as healthcare simulation.

1. Apply current guideline recommendations for escalation and de-escalation of inhaled therapies in patients with COPD
2. Select inhaler devices taking into consideration patient- and device-specific characteristics
3. Demonstrate proper inhaler technique for different inhalation devices
4. Provide recommended discharge and transitional care planning to patients COPD to improve outcomes

LAUNCH DATE/EXPIRATION DATE
This activity was launched on August 1, 2019 and will expire on August 1, 2020.
 
TARGET AUDIENCE
This activity has been designed to meet the educational needs of primary care clinicans, NPs, PAs and other health care professionals involved in the care of patients with COPD.

ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the providership of Horizon CME. Horizon CME is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION
Horizon CME designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
HOW TO CLAIM CREDIT
Statement of credit will be available to print from your user history page.
  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the post-test and activity evaluation.
  • Physicians who successfully complete the post-test and evaluation will receive CME credit.  You must score with a 75% or higher on the post-test to receive credit for this activity.
  • All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
LEARNER ASSURANCE STATEMENT
Horizon CME requires instructors, planners, managers and other individuals who are in a position to influence the content of this activity to disclose any real or apparent conflict of interest (COI) which may arise as a result of prospective faculty members' relevant relationships with drug or device manufacturer(s). Horizon CME is committed to resolving all conflicts of interest and retaining only those speakers with financial interest conflicts that can be reconciled with the goals and educational integrity of the CME activity.

Name of Faculty
Reported Financial Relationship
 Amit Singh Tibb, MD
Dr. Tibb discloses no relevant financial relationships with an ACCME/ANCC-defined commercial interest during the past 12 months.
 Emily Wan, MD, MPH
Dr. Wan discloses no relevant financial relationships with an ACCME/ANCC-defined commercial interest during the past 12 months.

OTHER CONTRIBUTOR/PLANNER DISCLOSURES

Eric Kleerup, MD provided external review for this activity.  Dr. Kleerup discloses no relevant financial relationships with an ACCME/ANCC-defined commercial interest during the past 12 months.

Additional non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 
 
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
 
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
 
SUPPORTER ACKNOWLEDGMENT
This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

COURSE VIEWING REQUIREMENTS
Supported Browsers:
Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6+ for Mac OSX 10.7 and above

For video playback, install the latest version of Flash or Quicktime.
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above